• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries - Product Image

Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries

  • ID: 1882218
  • September 2011
  • 171 Pages
  • GBI Research

FEATURED COMPANIES

  • Actelion
  • AstraZeneca
  • GlaxoSmithKline
  • Merck & Co., Inc.
  • Novartis
  • MORE

“Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries” provides insights into the global respiratory disorders market and market forecast until 2017. The report provides an in-depth analysis of the top seven respiratory disorders indications, which includes asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis. In addition, the report also includes insights into the respiratory disorders R&D pipeline. GBI research analysis estimated that 55% of the revenues are generated by AstraZeneca, GSK, Novartis, Merck, Roche, UCB Inc, Actelion and Takeda. Other companies generate 45% of the revenues in the respiratory disorders therapeutics market. AstraZeneca is the leading company in the respiratory disorders therapeutics market. The large amount of fragmentation in the market provides significant scope for consolidation through mergers and acquisitions. Strategic through acquisition accounted for 53% of the M&A deals.

The report is built using data and information sourced from proprietary databases, READ MORE >

FEATURED COMPANIES

  • Actelion
  • AstraZeneca
  • GlaxoSmithKline
  • Merck & Co., Inc.
  • Novartis
  • MORE

1
1 3
1.1 List of Tables 6
1.2 List of Figures 10
2 Respiratory Disorders Therapeutics Market to 2017 - Introduction 13
2.1 GBI Research Report Guidance 14
3 Respiratory Disorders Therapeutics Market to 2017 - Market Overview 15
3.1 Introduction 15
3.2 Revenue Forecasts for Respiratory Disorders Therapeutics Market 15
3.2.1 Revenues 15
3.2.2 Annual Cost of Therapy 20
3.3 Treatment Usage Patterns 21
3.4 Drivers and Barriers for Respiratory Disorders Therapeutics Market 23
3.4.1 Drivers for Respiratory Disorders 23
3.4.2 Barriers for Respiratory Disorders 24
4 Respiratory Disorders Therapeutics Market to 2017 - Geographical Landscape 25
4.1 The US 25
4.1.1 Revenue 25
4.1.2 Annual Cost of Therapy 26
4.1.3 Treatment Usage Pattern 27
4.2 Top Five Countries of Europe 29
4.2.1 Revenue 29
4.2.2 Annual Cost of Therapy 32
4.2.3 Treatment Usage Pattern 33
4.3 Japan 35
4.3.1 Revenue 35
4.3.2 Annual Cost of Therapy 36
4.3.3 Treatment Usage Pattern 37
5 Respiratory Disorders Therapeutics Market to 2017 - Therapeutic Landscape 39
5.1 Asthma 39
5.1.1 Introduction 39
5.1.2 Revenue 39
5.1.3 Annual Cost of Therapy 44
5.1.4 Treatment Usage Patterns 45
5.1.5 Treatment Flow Algorithm 47
5.1.6 Drivers and Barriers for Asthma 48
5.2 COPD 50
5.2.1 Introduction 50
5.2.2 Revenue 50
5.2.3 Annual Cost of Therapy 55
5.2.4 Treatment Usage Patterns 56
5.2.5 Treatment Flow Algorithm 58
5.2.6 Drivers and Barriers for COPD 59
5.3 Pulmonary Arterial Hypertension 60
5.3.1 Introduction 60
5.3.2 Revenue 62
5.3.3 Annual Cost of Therapy 66
5.3.4 Treatment Usage Patterns 67
5.3.5 Treatment Flow Algorithm 69
5.3.6 Drivers and Barriers for Pulmonary Arterial Hypertension 70
5.4 Cystic Fibrosis 71
5.4.1 Introduction 71
5.4.2 Revenue 71
5.4.3 Annual Cost of Therapy 76
5.4.4 Treatment Usage Patterns 77
5.4.5 Treatment Flow Algorithm 79
5.4.6 Drivers and Barriers for Cystic Fibrosis 80
5.5 Allergic Rhinitis 81
5.5.1 Introduction 81
5.5.2 Revenue 81
5.5.3 Annual Cost of Therapy 86
5.5.4 Treatment Usage Patterns 87
5.5.5 Treatment Flow Algorithm 88
5.5.6 Drivers and Barriers for Allergic Rhinitis 89
5.6 Idiopathic Pulmonary Fibrosis 90
5.6.1 Introduction 90
5.6.2 Revenue 90
5.6.3 Annual Cost of Therapy 94
5.6.4 Treatment Usage Patterns 95
5.6.5 Treatment Flow Algorithm 97
5.6.6 Drivers and Barriers for Idiopathic Pulmonary Fibrosis 98
5.7 Bronchitis 99
5.7.1 Introduction 99
5.7.2 Revenue 99
5.7.3 Annual Cost of Therapy 104
5.7.4 Treatment Usage Patterns 105
5.7.5 Treatment Flow Algorithm 107
5.7.6 Drivers and Barriers for Bronchitis 108
6 Respiratory Disorders Therapeutics Market to 2017 - Product Pipeline Analysis 109
6.1 Introduction 109
6.1.1 Research and Development Pipeline - Asthma 111
6.1.2 Research and Development Pipeline - COPD 117
6.1.3 Research and Development Pipeline - Pulmonary Arterial Hypertension 121
6.1.4 Research and Development Pipeline - Cystic Fibrosis 123
6.1.5 Research and Development Pipeline - Allergic Rhinitis 125
6.1.6 Research and Development Pipeline - Idiopathic Pulmonary Fibrosis 128
6.1.7 Research and Development Pipeline - Bronchitis 130
6.2 Profiles of Promising Drugs in the Respiratory Disorders Therapeutics Market 131
6.2.1 Bilastine 131
6.2.2 Sublivac (Extracts of Allergens) 131
6.2.3 Duonase (Azelastine + Fluticasone) 132
6.2.4 Riociguat 133
6.2.5 VX-770 133
6.2.6 Indacaterol 134
6.2.7 NVA237 (Glycopyrronium Bromide) 135
6.2.8 Aclidinium Bromide 136
7 Respiratory Disorders Therapeutics Market to 2017 - Competitive Landscape 137
7.1 Market Share Analysis: Respiratory Disorders Market 137
7.2 Drug Profile of Major Marketed Products 138
7.2.1 Advair Diskus (fluticasone propionate and salmeterol inhalation powder) 138
7.2.2 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) 140
7.2.3 Singulair (montekeulast sodium) 141
7.2.4 Tracleer 142
7.2.5 Nasonex (mometasone furoate monohydrate) 143
7.3 Competitive Profiling 145
7.3.1 AstraZeneca 145
7.3.2 GlaxoSmithKline 147
7.3.3 Merck & Co., Inc. 149
7.3.4 Actelion 151
7.3.5 Novartis 153
8 Respiratory Disorders Therapeutics Market to 2017 - M&A Landscape 155
8.1 M&A Landscape 155
8.1.1 M&A Deals by Year 155
8.1.2 M&A Deals by Value 156
8.1.3 M&A Deals by Value ($) 156
8.1.4 M&A Deals by Geography 157
8.1.5 M&A Deals by Deal Type 158
8.1.6 M&A Deals by Deal Sub-Type 159
8.2 R&D Licensing Agreements 160
8.2.1 Deals by Year 160
8.2.2 Deals by Geography 161
8.2.3 Deals by Value ($) 162
8.2.4 Licensing Agreements by Value ($) 162
8.3 Co-Development Agreements 163
8.3.1 Deals by Year 163
8.3.2 Deals by Geography 164
9 Respiratory Disorders Therapeutics Market to 2017 - Appendix 165
9.1 Market Definitions 165
9.2 Abbreviations 165
9.3 Research Methodology 166
9.3.1 Coverage 166
9.3.2 Secondary Research 166
9.3.3 Primary Research 167
9.3.4 Section Wise Methodology 167
9.3.5 Expert Panel Validation 170
9.4 Contact Us 170
9.5 Disclaimer 171
9.6 Sources 171

1.1 List of Tables
Table 1: Respiratory Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010 15
Table 2: Respiratory Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 16
Table 3: Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn), 2002-2010 17
Table 4: Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn), 2010-2017 18
Table 5: Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 20
Table 6: Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 20
Table 7: Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 21
Table 8: Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 22
Table 9: Respiratory Disorders Therapeutics Market, The US, Revenue, ($bn), 2002-2010 25
Table 10: Respiratory Disorders Therapeutics Market, The US, Revenue Forecasts, ($bn), 2010-2017 25
Table 11: Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2002-2010 26
Table 12: Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2010-2017 26
Table 13: Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002-2010 27
Table 14: Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns, (million), 2010-2017 28
Table 15: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue, ($bn), 2002-2010 29
Table 16: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue, ($bn), 2010-2017 29
Table 17: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Share by Country, ($bn), 2002-2010 30
Table 18: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($bn), 2010-2017 31
Table 19: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002-2010 32
Table 20: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2010-2017 32
Table 21: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002-2010 33
Table 22: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2010-2017 34
Table 23: Respiratory Disorders Therapeutics Market, Japan, Revenue, ($bn), 2002-2010 35
Table 24: Respiratory Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn), 2010-2017 35
Table 25: Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002-2010 36
Table 26: Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2010-2017 36
Table 27: Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002-2010 37
Table 28: Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2010-2017 38
Table 29: Asthma Therapeutics Market, Global, Revenue, ($bn), 2002-2010 40
Table 30: Asthma Therapeutics Market, Global, Revenue Forecasts, ($bn), 2010-2017 40
Table 31: Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2002-2010 41
Table 32: Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2010-2017 42
Table 33: Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 44
Table 34: Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 44
Table 35: Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010 45
Table 36: Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017 46
Table 37: COPD Therapeutics Market, Global, Revenue, ($m), 2002-2010 51
Table 38: COPD Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 51
Table 39: COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 52
Table 40: COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 53
Table 41: COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 55
Table 42: COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 55
Table 43: COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010 56
Table 44: COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017 57
Table 45: Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue, ($m), 2002-2010 62
Table 46: Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 62
Table 47: Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 63
Table 48: Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 64
Table 49: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 66
Table 50: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 66
Table 51: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2010 67
Table 52: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010-2017 67
Table 53: Cystic Fibrosis Therapeutics Market, Global, Revenue, ($m), 2002-2010 71
Table 54: Cystic Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 72
Table 55: Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 73
Table 56: Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 74
Table 57: Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 76
Table 58: Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 76
Table 59: Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2010 77
Table 60: Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010-2017 77
Table 61: Allergic Rhinitis Therapeutics Market, Global, Revenue, ($m), 2002-2010 81
Table 62: Allergic Rhinitis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 82
Table 63: Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 83
Table 64: Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 84
Table 65: Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 86
Table 66: Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 86
Table 67: Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 87
Table 68: Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 88
Table 69: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue, ($m) 2002-2010 90
Table 70: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m) 2010-2017 90
Table 71: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m) 2002-2010 91
Table 72: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m) 2010-2017 92
Table 73: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 94
Table 74: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($) 2010-2017 94
Table 75: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2010 95
Table 76: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010-2017 96
Table 77: Bronchitis Therapeutics Market, Global, Revenue ($m), 2002-2010 99
Table 78: Bronchitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 100
Table 79: Bronchitis Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2010 101
Table 80: Bronchitis Therapeutics Market, Global, Geographical Segmentation ($m), 2010-2017 102
Table 81: Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 104
Table 82: Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 104
Table 83: Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 105
Table 84: Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 105
Table 85: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Phase, 2011 109
Table 86: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Indication, 2011 110
Table 87: Asthma Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 111
Table 88: Asthma Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 111
Table 89: Asthma Therapeutics Market, Pipeline, Phase I Molecules, 2011 113
Table 90: Asthma Therapeutics Market, Pipeline, Phase II Molecules, 2011 114
Table 91: Asthma Therapeutics Market, Pipeline, Phase III Molecules, 2011 116
Table 92: Asthma Therapeutics Market, Pipeline, NDA Filed Molecules, 2011 116
Table 93: COPD Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 117
Table 94: COPD Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 117
Table 95: COPD Therapeutics Market, Pipeline, Phase I Molecules, 2011 118
Table 96: COPD Therapeutics Market, Pipeline, Phase II Molecules, 2011 119
Table 97: COPD Therapeutics Market, Pipeline, Phase III Molecules, 2011 120
Table 98: COPD Therapeutics Market, Pipeline, NDA Filed Molecules, 2011 120
Table 99: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 121
Table 100: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Phase I Molecules, 2011 121
Table 101: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Phase II Molecules, 2011 121
Table 102: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Phase III Molecules, 2011 122
Table 103: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, NDA Molecules, 2011 122
Table 104: Cystic Fibrosis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 123
Table 105: Cystic Fibrosis Therapeutics Market, Pipeline, Phase I Molecules, 2011 123
Table 106: Cystic Fibrosis Therapeutics Market, Pipeline, Phase II Molecules, 2011 123
Table 107: Cystic Fibrosis Therapeutics Market, Pipeline, Phase III Molecules, 2011 124
Table 108: Cystic Fibrosis Therapeutics Market, Pipeline, NDA Filed Molecules, 2011 124
Table 109: Allergic Rhinitis Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 125
Table 110: Allergic Rhinitis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 125
Table 111: Allergic Rhinitis Therapeutics Market, Pipeline, Phase I Molecules, 2011 125
Table 112: Allergic Rhinitis Therapeutics Market, Pipeline, Phase II Molecules, 2011 126
Table 113: Allergic Rhinitis Therapeutics Market, Pipeline, Phase III Molecules, 2011 127
Table 114: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 128
Table 115: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, IND Filed Molecules, 2011 128
Table 116: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Phase I Molecules, 2011 128
Table 117: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Phase II Molecules, 2011 128
Table 118: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Phase III Molecules, 2011 129
Table 119: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, NDA Filed Molecules, 2011 129
Table 120: Bronchitis Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011 130
Table 121: Bronchitis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011 130
Table 122: Bronchitis Therapeutics Market, Pipeline, Phase I Molecules, 2011 130
Table 123: Bronchitis Therapeutics Market, Pipeline, Phase II Molecules, 2011 130
Table 124: Bronchitis Therapeutics Market, Pipeline, Phase III Molecules, 2011 130
Table 125: Bronchitis Therapeutics Market, Pipeline, NDA Filed Molecules, 2011 130
Table 126: Respiratory Disorders Therapeutics Market to 2017, Sales of Major Marketed Products, ($m), 2010 138
Table 127: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Value ($m), 2004-2011 156
Table 128: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Geography, 2004-2011 157
Table 129: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Deal Type, 2004-2011 158
Table 130: Respiratory Disorders Therapeutics Market, Global, Deals by Deal Sub-Type, 2004-2011 159
Table 131: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Geography (%), 2004-2011 161
Table 132: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Value ($m), 2004-2011 162
Table 133: Respiratory Disorders Therapeutics Market, Global, Co-Development Agreements by Geography, 2004-2011 164

1.2 List of Figures
Figure 1: Respiratory Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 15
Figure 2: Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn), 2002-2017 17
Figure 3: Respiratory Disorders Therapeutics Market, Global, Branded and Generic Share (%), 2010 19
Figure 4: Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 20
Figure 5: Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 21
Figure 6: Respiratory Disorders Therapeutics Market, Global, Drivers and Barriers, 2010 23
Figure 7: Respiratory Disorders Therapeutics Market, The US, Revenue Forecasts, ($bn), 2002-2017 25
Figure 8: Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2002-2017 26
Figure 9: Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002-2017 27
Figure 10: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue Forecasts, ($bn), 2002-2017 29
Figure 11: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue Share by Country Forecasts, ($bn), 2002-2017 30
Figure 12: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002-2017 32
Figure 13: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002-2017 33
Figure 14: Respiratory Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn), 2002-2017 35
Figure 15: Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002-2017 36
Figure 16: Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002-2017 37
Figure 17: Asthma Therapeutics Market, Global, Revenue Forecasts, ($bn), 2002-2017 39
Figure 18: Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2002-2017 41
Figure 19: Asthma Therapeutics Market, Global, Branded and Generic Share, (%), 2010 43
Figure 20: Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 44
Figure 21: Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2017 45
Figure 22: Asthma Therapeutics Market, Global, Treatment Flow Algorithm, 2010 47
Figure 23: Asthma Therapeutics Market, Global, Drivers and Barriers, 2010 48
Figure 24: COPD Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 50
Figure 25: COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 52
Figure 26: COPD Therapeutics Market, Global, Branded and Generic Share, (%), 2010 54
Figure 27: COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 55
Figure 28: COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2017 56
Figure 29: COPD Therapeutics Market, Global, Treatment Flow Algorithm - 1, 2010 58
Figure 30: COPD Therapeutics Market, Global, Treatment Flow Algorithm - 2, 2010 58
Figure 31: COPD Therapeutics Market, Global, Drivers and Barriers, 2010 59
Figure 32: Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 62
Figure 33: Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 63
Figure 34: Pulmonary Arterial Hypertension Therapeutics Market, Global, Branded and Generic Share, (%), 2010 65
Figure 35: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 66
Figure 36: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2017 67
Figure 37: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Flow Algorithm, 2010 69
Figure 38: Pulmonary Arterial Hypertension Therapeutics Market, Global, Drivers and Barriers, 2010 70
Figure 39: Cystic Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 71
Figure 40: Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 73
Figure 41: Cystic Fibrosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 75
Figure 42: Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 76
Figure 43: Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2017 77
Figure 44: Cystic Fibrosis Therapeutics Market, Global, Treatment Flow Algorithm, 2010 79
Figure 45: Cystic Fibrosis Therapeutics Market, Global, Drivers and Barriers, 2010 80
Figure 46: Allergic Rhinitis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 81
Figure 47: Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017 83
Figure 48: Allergic Rhinitis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 85
Figure 49: Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 86
Figure 50: Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 87
Figure 51: Allergic Rhinitis Therapeutics Market, Global, Treatment Flow Algorithm, 2010 88
Figure 52: Allergic Rhinitis Therapeutics Market, Global, Drivers and Barriers, 2010 89
Figure 53: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m) 2002-2017 90
Figure 54: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m) 2002-2017 91
Figure 55: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 93
Figure 56: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017 94
Figure 57: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2017 95
Figure 58: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Flow Algorithm, 2010 97
Figure 59: Allergic Rhinitis Therapeutics Market, Global, Drivers and Barriers, 2010 98
Figure 60: Bronchitis Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 99
Figure 61: Bronchitis Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017 101
Figure 62: Bronchitis Therapeutics Market, Global, Branded and Generic Share (%), 2010 103
Figure 63: Bronchitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 104
Figure 64: Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 105
Figure 65: Bronchitis Therapeutics Market, Global, Treatment Flow Algorithm, 2010 107
Figure 66: Bronchitis Therapeutics Market, Global, Drivers and Barriers, 2010 108
Figure 67: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Phase (%), 2011 109
Figure 68: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Indication (%), 2011 110
Figure 69: Respiratory Disorders Therapeutics Market, Global, Market Share Analysis by Company (%), 2010 137
Figure 70: Respiratory Disorders Therapeutics Market, AstraZeneca, Company Overview, 2011 145
Figure 71: Respiratory Disorders Therapeutics Market, AstraZeneca, SWOT Analysis, 2011 146
Figure 72: Respiratory Disorders Therapeutics Market, GSK, Company Overview, 2011 147
Figure 73: Respiratory Disorders Therapeutics Market, GSK, SWOT Analysis, 2011 148
Figure 74: Respiratory Disorders Therapeutics Market, Merck, Company Overview, 2011 149
Figure 75: Respiratory Disorders Therapeutics Market, Merck, SWOT Analysis, 2011 150
Figure 76: Respiratory Disorders Therapeutics Market, Actelion, Company Overview, 2011 151
Figure 77: Respiratory Disorders Therapeutics Market, Actelion, SWOT Analysis, 2011 152
Figure 78: Respiratory Disorders Therapeutics Market, Novartis, Company Overview, 2011 153
Figure 79: Respiratory Disorders Therapeutics Market, Novartis, SWOT Analysis, 2011 154
Figure 80: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Year, 2004-2011 155
Figure 81: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Value (%), 2004-2011 156
Figure 82: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2011 157
Figure 83: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2011 158
Figure 84: Respiratory Disorders Therapeutics Market, Global, Deals by Deal Sub-Type (%), 2004-2011 159
Figure 85: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Year, 2004-2011 160
Figure 86: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Geography (%), 2004-2011 161
Figure 87: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Value (%), 2004-2011 162
Figure 88: Respiratory Disorders Therapeutics Market, Global, Co-Development Agreements by Year, 2004-2011 163
Figure 89: Respiratory Disorders Therapeutics Market, Global, Co-Development Agreements by Geography (%), 2004-2011 164
Figure 90: GBI Research Market Forecasting Model 169

FEATURED COMPANIES

  • Actelion
  • AstraZeneca
  • GlaxoSmithKline
  • Merck & Co., Inc.
  • Novartis
  • MORE

“Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries” provides insights into the global respiratory disorders market and market forecast until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides in-depth analysis of the major respiratory disorders. The report provides an in-depth analysis of the top seven respiratory disorders indications, which include asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis. The report examines the global respiratory disorders treatment usage patterns the US, the top five European countries and Japan. The report also includes insights into the respiratory disorders R&D product pipeline and explores the competitive landscape including major players in respiratory disorders market. Finally, the report includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in the respiratory disorders market.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Patent Expiries and Generic Competition Are Negatively Impacting upon the Market, Reducing its CAGR from 7.7% in 2002-2010 to 3.1% in 2010-2017

Source: GBI Research, Centre for Disease Prevention and Control (CDC),Food and Drug Administration (FDA), National Heart Lung and Blood Institute, American journal of Respiratory and Critical Medicine, Journal of Investigational Allergology and Clinical Immunology, Primary Care Respiratory Journal, Americanheart, AHA Journal, PH Association

The global respiratory therapeutics market was valued at $30.1 billion in 2010 and is expected to grow to $37.4 billion by 2017 at a Compound Annual Growth Rate (CAGR) of 3.1%. In 2010, approximately 49 million patients received pharmacological treatment for respiratory disorders with the annual cost of therapy being $611 per year. In addition, the annual cost of therapy for the respiratory disorders therapeutic area is expected to increase at a gradual rate over the following year. The respiratory disorders market growth rate will witness a decline during 2010-2017. This decline can be attributed to the patent expiries of certain branded products such as Tracleer (bosentan), Singulair (montelukast), Symbicort (budesonide and formoterol inhalation), Nasonex (mometasone furoate monohydrate), Rhinocort (budesonide) and Advair (fluticasone and salmeterol).

The market is projected to face increased competition from generic drugs. Patent expiries coupled with generic competition will reduce the annual cost of therapy in the forecast period. However, the annual cost of therapy will witness a moderate increase at a CAGR of 0.1% in the forecast period. This can be attributed to the launch of new pipeline molecules such as VX-770 and Riociguat (BAY 63-2521).

- AstraZeneca
- GlaxoSmithKline
- Merck & Co., Inc.
- Actelion
- Novartis

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos